[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511402":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":20,"locations":27,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":7,"overallStatus":30,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"BIOLOGICAL","Mepolizumab","Monoclonal antibodies",[14,15],"Omalizumab","Dupilumab",[17],{"name":18,"affiliation":5,"role":19},"Philippe Gevaert, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Manon Blauwblomme, Masters","CONTACT","+32 09 332 23 98","manon.blauwblomme@ugent.be",{"name":18,"role":23,"phone":7,"phoneExt":7,"email":7},[28],{"facility":29,"status":30,"city":31,"state":7,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Ghent University Hospital","RECRUITING","Ghent","9000","Belgium","BE",{"type":36,"coordinates":37},"Point",[38,39],3.71667,51.05,{"lat":39,"lon":38},[42,44],{"name":22,"role":23,"phone":43,"phoneExt":7,"email":25},"+32 09 332 23 95",{"name":18,"role":23,"phone":7,"phoneExt":7,"email":7},{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100511402","real-life-study-of-biologicals-in-patients-with-severe-crswnp-100511402",false,"NCT05938972","Real Life Study of Biologicals in Patients With Severe CRSwNP","Real Life Study Assessing Long Term Outcomes and Predictive Factors of Response to Biologicals in Patients With Severe CRSwNP and\u002For Severe Allergic and\u002For Eosinophilic Asthma","NASUMAB","Inclusion Criteria:\n\nPatients must meet the following criteria to be eligible for the enrolment in the study:\n\n* Signed informed consent form (ICF),\n* Age between 18 and 80 years at time of signing ICF,\n* Able to comply with the study protocol, in the investigator's judgment,\n* In group one: patients with severe allergic and\u002For eosinophilic asthma, defined by being currently treated with a biological (SoC) OR starting treatment with a biological (SoC).\n* In group two: patients with CRSwNP with or without asthma, defined by starting treatment with a biological (SoC) and fulfill the criteria for reimbursement of a biological therapy\n\nExclusion Criteria:\n\nPatients who do not meet the reimbursement criteria of a biological therapy cannot participate in the study.","ALL","18 Years","80 Years",{"count":59,"type":60},180,"ESTIMATED","24 Months","OBSERVATIONAL","This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment. The aim of this study is to observe the long-term outcomes of biologicals in CRSwNP patients with or without comorbid asthma in 'real life'. Moreover, the investigators will gain insight into the mechanisms of biologicals in the local and systemic immunity of these patients and investigate novel local and systemic biomarkers and predictors of response.",[65],"Chronic Rhinosinusitis With Nasal Polyps","2024-04-11",{"date":68,"type":69},"2024-04-15","ACTUAL",{"date":71,"type":69},"2022-03-01",{"date":73,"type":60},"2030-12-31",{"name":5,"class":6},1]